Full-Time
Posted on 7/10/2024
Develops precision oncology treatments for cancer
No salary listed
Junior, Mid
Boston, MA, USA
Upload your resume to see how it matches 2 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Scorpion Therapeutics develops precision oncology treatments aimed at targeting specific cancer drivers. Their approach involves creating drugs that interact with validated cancer targets, enhancing their selectivity and safety. This allows for more effective cancer treatments. Unlike many competitors, Scorpion Therapeutics focuses on forming partnerships with larger pharmaceutical companies for distribution, which enables them to concentrate on drug development while leveraging the resources of established firms. Their goal is to provide fast and precise cancer therapies that improve patient outcomes.
Company Size
51-200
Company Stage
Series C
Total Funding
$420M
Headquarters
Boston, Massachusetts
Founded
2020
Help us improve and share your feedback! Did you find this helpful?
In conjunction with the funding, Lightspeed Venture partner Shelley Chu will become an investor board member and Frazier Life Sciences managing partner Albert Cha will join the board of Scorpion as an observer.
Scorpion Therapeutics, a Boston, MA-based clinical-stage oncology company, raised $150M in Series C funding
Scorpion Therapeutics appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and expands Leadership Team.
Streit joined Scorpion in 2022 from Sanofi, where he had most recently served as vice president and senior project head.
Scorpion Therapeutics appoints precision medicine leader Jeff Albers as strategic advisor.